The Benefits of Rivaroxaban (Xarelto®) and the Relevance to Cardiologists
Ingo Ahrens, Christoph Bode
Cardiology and Angiology I, Heart Center Freiburg University, Freiburg, Germany
Disclosure: Authors have received speaker’s honoraria from Bayer Healthcare, Lilly, Sanofi Aventis, Daiichi Sankyo, Merck, and Astra-Zeneca.
Received: 29.08.13 Accepted: 07.10.13
Citation: EMJ Cardiol. 2013;1:XX-XX.
View this article in EMJ Cardiology 2013: http://viewer.zmags.com/publication/21e43266#/21e43266/115
Also available for download here: http://emjreviews.com/therapeutic-area/cardiology/benefits-rivaroxaban-xarelto-across-multiple-indications-relevance-cardiologists/
Year of Production: